JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

JNJ

239.47

+0.54%↑

UNH

276.79

+3.23%↑

TMO

542.02

-2.02%↓

ABT

109.96

+0.76%↑

ISRG

489.76

+1.33%↑

Search

Heron Therapeutics Inc

Abrir

SetorSaúde

1.24 -0.8

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.18

Máximo

1.26

Indicadores-chave

By Trading Economics

Rendimento

-15M

-17M

Vendas

1M

38M

Margem de lucro

-45.783

Funcionários

122

EBITDA

-12M

-14M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+240.91% upside

Dividendos

By Dow Jones

Próximos Ganhos

26 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

37M

253M

Abertura anterior

2.04

Fecho anterior

1.24

Sentimento de Notícias

By Acuity

33%

67%

77 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Heron Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de fev. de 2026, 23:57 UTC

Ganhos

Naver Has Record Year Despite Weaker Final Quarter

5 de fev. de 2026, 23:45 UTC

Ações em Alta

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5 de fev. de 2026, 22:26 UTC

Ganhos

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5 de fev. de 2026, 22:00 UTC

Ganhos

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5 de fev. de 2026, 23:47 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

5 de fev. de 2026, 23:47 UTC

Conversa de Mercado

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5 de fev. de 2026, 23:43 UTC

Conversa de Mercado

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5 de fev. de 2026, 23:37 UTC

Conversa de Mercado

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5 de fev. de 2026, 23:20 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5 de fev. de 2026, 23:11 UTC

Conversa de Mercado

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5 de fev. de 2026, 23:09 UTC

Ganhos

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5 de fev. de 2026, 23:08 UTC

Ganhos

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5 de fev. de 2026, 23:07 UTC

Ganhos

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5 de fev. de 2026, 23:03 UTC

Conversa de Mercado
Ganhos

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5 de fev. de 2026, 23:03 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5 de fev. de 2026, 23:00 UTC

Ganhos

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5 de fev. de 2026, 23:00 UTC

Ganhos

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5 de fev. de 2026, 22:59 UTC

Ganhos

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5 de fev. de 2026, 22:59 UTC

Ganhos

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5 de fev. de 2026, 22:52 UTC

Ganhos

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5 de fev. de 2026, 22:45 UTC

Ganhos

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5 de fev. de 2026, 22:37 UTC

Conversa de Mercado

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5 de fev. de 2026, 22:11 UTC

Ganhos

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5 de fev. de 2026, 22:03 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5 de fev. de 2026, 22:01 UTC

Ganhos

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5 de fev. de 2026, 21:59 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5 de fev. de 2026, 21:51 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5 de fev. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Basic Materials Roundup: Market Talk

5 de fev. de 2026, 21:49 UTC

Ganhos

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5 de fev. de 2026, 21:45 UTC

Ganhos

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Comparação entre Pares

Variação de preço

Heron Therapeutics Inc Previsão

Preço-alvo

By TipRanks

240.91% parte superior

Previsão para 12 meses

Média 4.5 USD  240.91%

Máximo 6 USD

Mínimo 3 USD

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Heron Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

2

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

2.0001 / 2.42Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

77 / 352 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat